Clinical trials: Patients with Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis RRMS
A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®
This was a 3-year, prospective, multi-center, open-label study to describe the long term changes of optical coherence tomography (OCT) parameters in RRMS patients under treatment with Fingolimod.
- Trial name
- PASSOS (NCT01705236)
- Testing
- Fingolimod
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 87 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.
- Trial name
- START (NCT01585298)
- Testing
- FTY720
- Where
- 258 sites in Germany
- Volunteers
- 6,998 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Reeducation Program to Effort to Improve the Walking of Multiple Sclerosis Patients
Multiple sclerosis (MS) is a disease affecting the white matter of the central nervous system. In France, it concerns approximately 80 000 patients and represents one of the most frequent neurological affections in young adults.
- Trial name
- AEROSEP (NCT02874677)
- Testing
- Effort reeducation program
- Where
- 4 sites in France
- Volunteers
- 46 people
- Sponsor
- Lille Catholic University
Relapsing-Remitting Multiple Sclerosis
Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis
Multiple Sclerosis is a very disabling disorder in young adult patients leading to an important limitation in daily life activities and social participation.
- Trial name
- NCT01564511
- Testing
- Gait trainer treatment, Conventional treatment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Universita di Verona
Relapsing-remitting Multiple Sclerosis (RRMS)
A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
The purpose of the study is to collect clinical data on the persistence with ozanimod treatment, as well as to describe its effects on participant-relevant outcome parameters in treatment-naïve participants with RRMS.
- Trial name
- AppreZiate (NCT05811416)
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis (MS), Cerebral Small Vessel Diseases
MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis
This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS).
- Trial name
- NCT07444047
- Where
- Norway
- Volunteers
- 1,000 people
- Sponsor
- Oslo University Hospital
Multiple Sclerosis
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
The primary objective is to assess the quality of life of intramuscular (IM) Interferon Beta-1a in participants with relapsing remitting multiple sclerosis (RRMS) or Clinically Isolated Syndrome (CIS) in a clinical practice…
- Trial name
- AVAIL (NCT01272128)
- Testing
- Interferon beta-1a
- Where
- 17 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Biogen
Multiple Sclerosis
Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis
Twenty four relapsing-remitting multiple sclerosis (RRMS) patients over the age of 18, with similar degree of disability, and with an evolution of at last 6 months, who are in first-line immunomodulatory therapy and have a stable…
- Trial name
- NCT02280096
- Testing
- 4-aminopyridine
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Multiple Sclerosis
Tecfidera Slow-Titration Study
The primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of dimethyl fumarate (DMF [Tecfidera])-related gastrointestinal (GI) adverse…
- Trial name
- TITRATION (NCT02428231)
- Testing
- dimethyl fumarate
- Where
- 20 sites in United States, Belgium and 2 more
- Volunteers
- 62 people
- Sponsor
- Biogen
Multiple Sclerosis, Magnetic Resonance Spectroscopy
MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis
The transition from relapsing-remitting multiple sclerosis to secondarily progressive multiple sclerosis (SPMS) is difficult to identify.
- Trial name
- NCT05491031
- Testing
- magnetic resonance spectroscopy
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Poitiers University Hospital
Relapsing-Remitting Multiple Sclerosis
Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy
The primary objective of the study is to investigate whether topical Vitamin K application reduces the grade of erythema in comparison with a vehicle cream (placebo) through physicians' assessment and participant self-assessment.
- Trial name
- VITALITY (NCT03091569)
- Testing
- Vitamin K Cream
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Biogen
Progressive Multifocal Leukoencephalopathy
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
The primary purpose of this study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) among patients who switched to Tysabri from disease modifying therapies (DMTs), including newer DMTs (including…
- Trial name
- NCT03399981
- Testing
- Tysabri
- Where
- United States
- Volunteers
- 80,327 people
- Sponsor
- Biogen
Radiologically Isolated Syndrome, Multiple Sclerosis
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 4 study in which eligible patients with RADIOLOGICALLY ISOLATED SYNDROME (RIS) (as defined by meeting 2017 McDonald criteria for DIS) will be randomized…
- Trial name
- CELLO (NCT04877457)
- Testing
- Ocrelizumab
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- ReWRAP (NCT04002934)
- Testing
- Bazedoxifene Acetate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Riley Bove, MD
Relapsing Multiple Sclerosis
A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
Open-label, long-term extension study available to participants who have completed CNMAu8.201.
- Trial name
- VISIONMS-LTE (NCT04626921)
- Testing
- CNM-Au8
- Where
- 5 sites in Australia
- Volunteers
- 55 people
- Sponsor
- Clene Nanomedicine
Malignant PEComa (Perivascular Epithelioid Cell Tumors)
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
Study objectives: The primary objective is to determine the efficacy of BEZ235 on Objective Response Rate (best response on study) according to RECIST 1.1 criteria The secondary objectives are: To determine the progression free…
- Trial name
- NCT01690871
- Testing
- BEZ235
- Where
- Spain
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Obesity
The Effect of Obesity on Contralateral Suppression in Patients With Multiple Sclerosis
This study investigates how obesity may affect the auditory system in individuals with Multiple Sclerosis (MS). Specifically, it examines the brain's ability to process and suppress sounds (contralateral suppression).
- Conditions
- Multiple Sclerosis, Obesity, Hearing Loss
- Trial name
- MS (NCT07136311)
- Testing
- DPOAE with Contralateral Suppression
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people
- Sponsor
- Ondokuz Mayıs University
Relapsing-Remitting Multiple Sclerosis
fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
Impaired short term memory, attention and concentration lapses, and slower processing of information occur in up to 40-65% of patients with Multiple Sclerosis (MS).
- Trial name
- NCT00391352
- Testing
- IFN-β-1a (Rebif®)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Waukesha Memorial Hospital
Relapsing-remitting Multiple Sclerosis
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
The purpose of this study is to compare the injection site reaction and injection site pain after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different autoinjectors.
- Trial name
- NCT00317941
- Testing
- Betaferon/Betaseron, Rebif
- Where
- 59 sites in France
- Volunteers
- 220 people
- Sponsor
- Bayer
Autoimmune Disease, Neurologic Autoimmune Disease
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic…
- Conditions
- Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant
- Trial name
- NCT00716066
- Testing
- Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.